Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
Latest Information Update: 16 Jun 2025
At a glance
- Drugs Zoldonrasib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors REVOLUTION Medicines
Most Recent Events
- 30 Apr 2025 Results assessing the preliminary safety and antitumor activity of zoldonrasib RMC-9805 in patients with KRAS G12D non-small cell lung cancer from a phase 1 study in advanced solid tumors were published at the 116th Annual Meeting of the American Association for Cancer Research.
- 27 Apr 2025 According to a Revolution Medicines media release, Kathryn Arbour, M.D., thoracic medical oncologist at Memorial Sloan Kettering Cancer Center is the principal investigator of this trial.
- 27 Apr 2025 According to a Revolution Medicines media release, initial data from this trial were featured in a late-breaking oral presentation on April 27, 2025, at 5:00 p.m. Central Time, in the official press program at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois.